Weight-related safety outcomes of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder
Michel Lecendreux(Laboratoire National de Référence), David Coghill(The University of Melbourne), Alessandro Zuddas(University of Cagliari), César A. Soutullo(The University of Texas Health Science Center), Ralph Bloomfield(AstraZeneca (United Kingdom)), Maria Gasior(Takeda (United States)), Paul Hodgkins(Takeda (United States)), Tobias Banaschewski(Heidelberg University)
European Child & Adolescent Psychiatry
January 1, 2013
Cited by 0
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders
|Cell|2019|1.5k
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
|Neuroscience & Biobehavioral Reviews|2021|1.4k
Attention-deficit/hyperactivity disorder
|Nature Reviews Disease Primers|2015|1.3k